http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3151831-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed241b5f4f42e683b688f5858eab6a46 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2510-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate | 2015-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9beccb786a0c8ab01d1767de9e222a11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc5a6c9e6c5659885032db41e8b8b5e |
| publicationDate | 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3151831-A1 |
| titleOfInvention | Priming of cancer cells with low dose naltrexone |
| abstract | The present invention provides a pharmaceutical composition comprising naltrexone or an analogue thereof for use in the treatment of a subject having a tumour/cancer; wherein the naltrexone or the analogue thereof is to be administered to the subject in a first treatment phase, followed by a recovery phase; wherein, following the recovery phase, a small molecule signalling inhibitor selected from the group consisting of PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and cell cycle inhibitors is to be administered to the subject in a second treatment phase; the recovery phase being characterised by the absence of administration of the naltrexone or the analogue thereof and the small molecule signalling inhibitor. Also envisaged are a diagnostic test to assess the response of a subject to the first treatment phase, an in vitro method of testing the efficacy of a small molecule signalling inhibitor when for use in combination with naltrexone, and the use of naltrexone in such a method when in vivo. |
| priorityDate | 2014-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.